【摘要】：目的觀察前列舒通膠囊聯(lián)合α-1A受體阻滯劑治療濕熱瘀阻III型前列腺炎的臨床療效 方法將121例濕熱瘀阻III型前列腺炎患者隨機分為治療組和對照組，分別給予前列舒通膠囊（3粒，，每天3次)+鹽酸坦洛新膠囊(0.2mg，每晚1次)和鹽酸坦洛新膠囊(0.2mg，每晚1次)治療，8周后按照美國國立衛(wèi)生研究所(NIH)制定的前列腺癥狀評分標準（CPSI）和勃起功能國際問卷(IIEF一5)量化兩組患者的癥狀積分，并觀察治療前后前列腺液中卵磷脂小體白細胞計數(shù)和PH值的變化，比較兩組患者的臨床療效及其副作用 結(jié)果經(jīng)過8周的治療，治療組和對照組的NIH-CPSI評分QOL評分及EPS常規(guī)中白細胞數(shù)目均有顯著下降（P0．01），但治療組下降的程度均較對照組明顯（P0．01）；治療組和對照組的IIEF一5評分均明顯上升，治療組升高程度較對照組明顯（P0．01） 結(jié)論前列舒通膠囊聯(lián)合α-1A受體阻滯劑治療濕熱瘀阻型III型前列腺炎比單用α-1A受體阻滯劑療效明顯，值得臨床推廣
[Abstract]:Objective to observe the clinical efficacy of Qianlieshutong capsule combined with 偽-1A receptor blocker in the treatment of type III prostatitis with damp-heat stasis. Methods 121 cases of type III prostatitis with damp-heat stasis were randomly divided into treatment group and control group. Qianlie Shutong capsule (3 tablets, 3 times a day) and Tanloxin Hydrochloride capsule (0.2 mg, once a night) and Tanloxin Hydrochloride capsule (0.2 mg, once a night) were given, respectively, and were treated with Tanloxin Hydrochloride capsule (0.2 mg, once a night). Eight weeks later, the symptom scores of the two groups were quantified according to the Prostate symptom score Standard (CPSI) developed by the National Institutes of Health (NIH) and the International scale for erectile function (IIEF-5). We also observed the changes of leucocyte count and PH value in prostatic fluid before and after treatment, and compared the clinical efficacy and side effects of the two groups after 8 weeks of treatment. In the treatment group and the control group, the NIH-CPSI score QOL score and the number of white blood cells in the EPS routine were significantly decreased (P0.01), but the degree of decrease in the treatment group was more obvious than that in the control group (P0.01). The IIEF-5 scores in the treatment group and the control group were significantly higher than those in the control group. Conclusion Qianliesutong capsule combined with 偽-1A receptor blocker is more effective than 偽-1A receptor blocker alone in the treatment of type III prostatitis, which is worthy of clinical popularization.
【學(xué)位授予單位】：甘肅中醫(yī)學(xué)院
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2014
【分類號】：R697.33

【參考文獻】

相關(guān)期刊論文 前10條

1 趙而立;中西醫(yī)結(jié)合治療慢性前列腺炎48例臨床觀察[J];中國醫(yī)藥學(xué)報;2004年08期

2 黃霄;;中西醫(yī)結(jié)合治療慢性前列腺炎臨床觀察[J];長春中醫(yī)藥大學(xué)學(xué)報;2011年01期

3 趙潤璞;張向輝;;前列舒通膠囊治療濕熱瘀阻型慢性前列腺炎臨床觀察[J];當代醫(yī)學(xué);2009年31期

4 劉寧飛;辨證治療慢性前列腺炎50例[J];湖南中醫(yī)藥導(dǎo)報;1997年Z1期

5 李雄偉;;血府逐瘀湯聯(lián)合洛美沙星治療慢性非細菌性前列腺炎60例[J];河南中醫(yī);2008年11期

6 牟吉榮,徐剛;從瘀論治慢性前列腺炎136例[J];江西中醫(yī)藥;2001年04期

7 石志超;從血瘀精道論治慢性前列腺炎[J];遼寧中醫(yī)雜志;2001年11期

8 陳朋飛;孫自學(xué);;自擬通絡(luò)清解方治療慢性前列腺炎濕熱瘀阻型120例臨床觀察[J];遼寧中醫(yī)雜志;2012年04期

9 張敏建,郭軍;疏肝理氣法治療慢性非細菌性前列腺炎的臨床研究[J];中華男科學(xué);2002年01期

10 楊紹波,劉屹立,孔垂?jié)?李明;西地那非對前列腺炎相關(guān)的性功能障礙的干預(yù)研究[J];中華男科學(xué);2004年06期

本文編號：2443878